Cargando…

Medication nonadherence among South American patients with schizophrenia

OBJECTIVE: The objective of this research was to quantify nonadherence to medication and explore the determinants of nonadherence in patients diagnosed with schizophrenia (SZ) from three countries in Latin America (Bolivia, Peru, and Chile). METHODS: This study was conducted in public mental health...

Descripción completa

Detalles Bibliográficos
Autores principales: Caqueo-Urízar, Alejandra, Urzúa, Alfonso, Fond, Guillaume, Boyer, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640421/
https://www.ncbi.nlm.nih.gov/pubmed/29070941
http://dx.doi.org/10.2147/PPA.S144961
_version_ 1783271041542389760
author Caqueo-Urízar, Alejandra
Urzúa, Alfonso
Fond, Guillaume
Boyer, Laurent
author_facet Caqueo-Urízar, Alejandra
Urzúa, Alfonso
Fond, Guillaume
Boyer, Laurent
author_sort Caqueo-Urízar, Alejandra
collection PubMed
description OBJECTIVE: The objective of this research was to quantify nonadherence to medication and explore the determinants of nonadherence in patients diagnosed with schizophrenia (SZ) from three countries in Latin America (Bolivia, Peru, and Chile). METHODS: This study was conducted in public mental health centers in Bolivia, Peru, and Chile. The data collected included drug attitude inventory (DAI-10), sociodemographic information, and clinical and treatment characteristics of patients with SZ. Multivariate analysis with multiple linear regression was then performed to identify variables that were potentially associated with the DAI score (dependent variable). RESULTS: Two hundred and fifty-three patients diagnosed with SZ participated in the study and 247 fully completed the DAI-10. In the multivariate analysis, medication nonadherence was associated with being a woman (β=−0.16, p=0.029), younger age (β=0.17, p=0.020), younger age at onset of disease (β=−0.17, p=0.019), and lower insight (β=−0.30, p<0.001). CONCLUSION: Being a female, younger age, younger age at onset of disease, and lower insight were the main features associated with nonadherence. If future longitudinal studies confirm these findings, these factors should not be neglected in Latin American mental health public policies to address the problem of nonadherence.
format Online
Article
Text
id pubmed-5640421
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-56404212017-10-25 Medication nonadherence among South American patients with schizophrenia Caqueo-Urízar, Alejandra Urzúa, Alfonso Fond, Guillaume Boyer, Laurent Patient Prefer Adherence Original Research OBJECTIVE: The objective of this research was to quantify nonadherence to medication and explore the determinants of nonadherence in patients diagnosed with schizophrenia (SZ) from three countries in Latin America (Bolivia, Peru, and Chile). METHODS: This study was conducted in public mental health centers in Bolivia, Peru, and Chile. The data collected included drug attitude inventory (DAI-10), sociodemographic information, and clinical and treatment characteristics of patients with SZ. Multivariate analysis with multiple linear regression was then performed to identify variables that were potentially associated with the DAI score (dependent variable). RESULTS: Two hundred and fifty-three patients diagnosed with SZ participated in the study and 247 fully completed the DAI-10. In the multivariate analysis, medication nonadherence was associated with being a woman (β=−0.16, p=0.029), younger age (β=0.17, p=0.020), younger age at onset of disease (β=−0.17, p=0.019), and lower insight (β=−0.30, p<0.001). CONCLUSION: Being a female, younger age, younger age at onset of disease, and lower insight were the main features associated with nonadherence. If future longitudinal studies confirm these findings, these factors should not be neglected in Latin American mental health public policies to address the problem of nonadherence. Dove Medical Press 2017-10-06 /pmc/articles/PMC5640421/ /pubmed/29070941 http://dx.doi.org/10.2147/PPA.S144961 Text en © 2017 Caqueo-Urízar et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Caqueo-Urízar, Alejandra
Urzúa, Alfonso
Fond, Guillaume
Boyer, Laurent
Medication nonadherence among South American patients with schizophrenia
title Medication nonadherence among South American patients with schizophrenia
title_full Medication nonadherence among South American patients with schizophrenia
title_fullStr Medication nonadherence among South American patients with schizophrenia
title_full_unstemmed Medication nonadherence among South American patients with schizophrenia
title_short Medication nonadherence among South American patients with schizophrenia
title_sort medication nonadherence among south american patients with schizophrenia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640421/
https://www.ncbi.nlm.nih.gov/pubmed/29070941
http://dx.doi.org/10.2147/PPA.S144961
work_keys_str_mv AT caqueourizaralejandra medicationnonadherenceamongsouthamericanpatientswithschizophrenia
AT urzuaalfonso medicationnonadherenceamongsouthamericanpatientswithschizophrenia
AT fondguillaume medicationnonadherenceamongsouthamericanpatientswithschizophrenia
AT boyerlaurent medicationnonadherenceamongsouthamericanpatientswithschizophrenia